Adrenoleukodystrophy - Pipeline Review, H1 2017
Adrenoleukodystrophy - Pipeline Review, H1 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Pipeline Review, H1 2017, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.
Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.
Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Pipeline Review, H1 2017, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.
Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.
Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Overview
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Companies Involved in Therapeutics Development
bluebird bio Inc
MedDay SA
Minoryx Therapeutics sl
Pfizer Inc
ReceptoPharm Inc
Viking Therapeutics Inc
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drug Profiles
biotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DRX-065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ABCD1 for Adrenoleukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lenti-D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGTA-456 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pioglitazone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPI-78M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
temsirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-0214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-2809 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Product Development Milestones
Featured News & Press Releases
Mar 21, 2017: Minoryx Therapeutics successfully completes phase 1 clinical trial for lead candidate MIN-102
Feb 22, 2017: Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102
Jan 18, 2017: Minoryx Therapeutics further strengthens its Scientific Advisory Board (SAB)
Dec 14, 2016: Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102
Dec 06, 2016: Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
Sep 26, 2016: Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy at the 86th Annual Meeting of the American Thyroid Association
Sep 14, 2016: Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016
Jul 26, 2016: Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Jul 06, 2016: Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102
Jun 14, 2016: Minoryx Therapeutics appoints Dr. Uwe Meya as Chief Medical Officer
Apr 03, 2014: Minoryx receives Orphan Drug Designation for MIN-101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Overview
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Companies Involved in Therapeutics Development
bluebird bio Inc
MedDay SA
Minoryx Therapeutics sl
Pfizer Inc
ReceptoPharm Inc
Viking Therapeutics Inc
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drug Profiles
biotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DRX-065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ABCD1 for Adrenoleukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lenti-D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGTA-456 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pioglitazone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPI-78M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
temsirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-0214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-2809 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Product Development Milestones
Featured News & Press Releases
Mar 21, 2017: Minoryx Therapeutics successfully completes phase 1 clinical trial for lead candidate MIN-102
Feb 22, 2017: Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102
Jan 18, 2017: Minoryx Therapeutics further strengthens its Scientific Advisory Board (SAB)
Dec 14, 2016: Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102
Dec 06, 2016: Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
Sep 26, 2016: Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy at the 86th Annual Meeting of the American Thyroid Association
Sep 14, 2016: Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016
Jul 26, 2016: Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Jul 06, 2016: Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102
Jun 14, 2016: Minoryx Therapeutics appoints Dr. Uwe Meya as Chief Medical Officer
Apr 03, 2014: Minoryx receives Orphan Drug Designation for MIN-101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Applied Genetic Technologies Corp, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by bluebird bio Inc, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by MedDay SA, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Minoryx Therapeutics sl, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Pfizer Inc, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by ReceptoPharm Inc, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Viking Therapeutics Inc, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects, H1 2017
Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Applied Genetic Technologies Corp, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by bluebird bio Inc, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by MedDay SA, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Minoryx Therapeutics sl, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Pfizer Inc, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by ReceptoPharm Inc, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Viking Therapeutics Inc, H1 2017
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects, H1 2017
LIST OF FIGURES
Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
bluebird bio Inc
MedDay SA
Minoryx Therapeutics sl
Pfizer Inc
ReceptoPharm Inc
Viking Therapeutics Inc
Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
bluebird bio Inc
MedDay SA
Minoryx Therapeutics sl
Pfizer Inc
ReceptoPharm Inc
Viking Therapeutics Inc
